Orphan designation: 2-(2-(2-[2-(4-Benzothiazol-2-yl-phenoxy)-ethoxy]-ethoxy)-ethoxy)-ethanol Treatment of amyotrophic lateral sclerosis, 20/06/2025 Positive

Submitted by Anonymous (not verified) on 17 July 2025 - 13:56

Orphan designation: 2-(2-(2-[2-(4-Benzothiazol-2-yl-phenoxy)-ethoxy]-ethoxy)-ethoxy)-ethanol Treatment of amyotrophic lateral sclerosis, 20/06/2025 Positive

Orphan designation: sodium 2-(3'(-3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-ethoxy-[1,1'-biphenyl]-3-yl)acetate Treatment of hepatocellular carcinoma, 20/06/2025 Positive

Submitted by Anonymous (not verified) on 17 July 2025 - 13:55

Orphan designation: sodium 2-(3'(-3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-ethoxy-[1,1'-biphenyl]-3-yl)acetate Treatment of hepatocellular carcinoma, 20/06/2025 Positive

Human medicines European public assessment report (EPAR): Ivabradine Zentiva, ivabradine, Date of authorisation: 11/11/2016, Revision: 7, Status: Authorised

Submitted by Anonymous (not verified) on 17 July 2025 - 13:39

Human medicines European public assessment report (EPAR): Ivabradine Zentiva, ivabradine, Date of authorisation: 11/11/2016, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Javlor, vinflunine, Date of authorisation: 21/09/2009, Revision: 12, Status: Authorised

Submitted by Anonymous (not verified) on 16 July 2025 - 16:01

Human medicines European public assessment report (EPAR): Javlor, vinflunine, Date of authorisation: 21/09/2009, Revision: 12, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More